<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03744026</url>
  </required_header>
  <id_info>
    <org_study_id>SC9-GBM-01</org_study_id>
    <nct_id>NCT03744026</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Transient Opening of the Blood-brain Barrier (BBB) With the SonoCloud-9</brief_title>
  <acronym>SC9-GBM-01</acronym>
  <official_title>A Study to Evaluate the Safety and the Efficacy of Transient Opening of the Blood-brain Barrier (BBB) by Low Intensity Pulsed Ultrasound With the SonoCloud-9 Implantable Device in Recurrent Glioblastoma Patients Eligible for Surgery and for Carboplatin Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CarThera</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CarThera</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recurrent glioblastoma (GBM) is a disease with high unmet clinical need. The standard of care&#xD;
      for patients with GBM includes surgery, radiotherapy and chemotherapy. Despite this&#xD;
      aggressive treatment, the overall median survival of patients with GBM remains at 15-20&#xD;
      months.&#xD;
&#xD;
      In more than 95% of cases, tumor recurrence is observed within 2 cm to 3 cm of the resection&#xD;
      cavity within 4-7 months after initial treatments. One of the main causes of recurrence is&#xD;
      the inability of chemotherapies to enter the brain from the systemic circulation due to the&#xD;
      blood-brain barrier (BBB). The BBB is unique to cerebral blood vessels and blocks most drugs&#xD;
      from entering the brain in sufficient concentrations.&#xD;
&#xD;
      The SonoCloud-9 (SC9) System delivers ultrasound to locally and transiently increase the&#xD;
      permeability of the BBB to allow the passage of drugs into the cerebral parenchyma. The SC9&#xD;
      is dimensioned to cover the resection area and surrounding tissues in patients with recurrent&#xD;
      GBM. The large sonicated volume covered by the SC9 device allows for broad BBB disruption and&#xD;
      should allow for carboplatin chemotherapy to penetrate the surrounding tumor infiltrative&#xD;
      area. By enhancing drug concentrations, it is hypothesized that further disease progression&#xD;
      will be prevented.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be an open-label, Phase 1/2a, multicenter, single-arm, interventional trial that&#xD;
      will first evaluate the dose limiting toxicity (DLT) of escalating numbers of ultrasound&#xD;
      beams at constant acoustic pressure using a standard escalation (Phase 1) and then confirm&#xD;
      the safety and efficacy of BBB opening (Phase 2a expansion).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 18, 2019</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Actual">June 23, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose limiting toxicity (DLT) of number of activated ultrasound beams</measure>
    <time_frame>15 days after the first sonication treatment</time_frame>
    <description>DLT will be evaluated using imaging (MRI) and clinical examination, as CTCAE that occurs within 2 weeks of the first sonication and that does not respond to optimal medical management (including steroids) within 7 days.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood-Brain Barrier (BBB) opening</measure>
    <time_frame>At the end of the first three sonication treatments (treatment occurs every 4 weeks)</time_frame>
    <description>BBB opening will be evaluated by contrast-enhanced T1w magnetic resonance imaging (MRI)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">33</enrollment>
  <condition>Glioblastoma, Adult</condition>
  <arm_group>
    <arm_group_label>SonoCloud-9 Ultrasound + Carboplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SonoCloud-9 Carboplatin: 6 cycles (every 4 weeks)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SonoCloud-9</intervention_name>
    <description>Escalating numbers of ultrasound beams at constant acoustic pressure</description>
    <arm_group_label>SonoCloud-9 Ultrasound + Carboplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Dose of carboplatin infusion is AUC4-6</description>
    <arm_group_label>SonoCloud-9 Ultrasound + Carboplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 18 years, able and willing to give signed and informed consent.&#xD;
&#xD;
          2. Patient with histologically proven recurrent de novo GBM:&#xD;
&#xD;
               1. After at least a first-line standard of care (maximal safe resection, if&#xD;
                  feasible, radiation with temozolomide [TMZ], then TMZ);&#xD;
&#xD;
               2. Any recurrence;&#xD;
&#xD;
               3. Bevacizumab-naïve.*&#xD;
&#xD;
          3. Patient eligible for carboplatin-based chemotherapy.&#xD;
&#xD;
          4. Patient eligible for a surgical resection.&#xD;
&#xD;
          5. Maximal tumor diameter at inclusion (pre surgery) ≤ 70 mm in T1wMRI.&#xD;
&#xD;
          6. Patients should be stable, without evidence of a midline shift, significant&#xD;
             peritumoral edema, or rapid progression of clinical symptoms.&#xD;
&#xD;
          7. Karnofsky performance status ≥ 70.&#xD;
&#xD;
          8. Patient receiving prednisone dose ≤ 40 mg (dexamethasone ≤ 6 mg) for at least 7 days.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. Multifocal tumor (unless all localized in a 70 mm diameter area).&#xD;
&#xD;
          2. Patients at risk of surgery site infection (2 or more previous craniotomies,&#xD;
             neurosurgery within the last 3 months, poor skin condition, and/or previously infected&#xD;
             surgical field).&#xD;
&#xD;
          3. Posterior fossa tumor.&#xD;
&#xD;
          4. Uncontrolled epilepsy.&#xD;
&#xD;
          5. Patients with evidence of uncontrolled intracranial pressure.&#xD;
&#xD;
          6. Patients with known intracranial aneurism or having presented intra-tumor spontaneous&#xD;
             hemorrhage.&#xD;
&#xD;
          7. Patients with coils, clips, shunts, intravascular stents, and/or unremovable wafer,&#xD;
             non resorbable dura substitute, or reservoirs.&#xD;
&#xD;
          8. Patients with medical need to continue antiplatelet therapy.&#xD;
&#xD;
          9. Patients with known or suspected active or chronic infections.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmed IDBAIH, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>APHP</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Neurologique Pierre Wertheimer</name>
      <address>
        <city>Bron</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de La Timone</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Pitié-Salpêtrière</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.carthera.eu</url>
    <description>CarThera</description>
  </link>
  <reference>
    <citation>Carpentier A, Canney M, Vignot A, Reina V, Beccaria K, Horodyckid C, Karachi C, Leclercq D, Lafon C, Chapelon JY, Capelle L, Cornu P, Sanson M, Hoang-Xuan K, Delattre JY, Idbaih A. Clinical trial of blood-brain barrier disruption by pulsed ultrasound. Sci Transl Med. 2016 Jun 15;8(343):343re2. doi: 10.1126/scitranslmed.aaf6086.</citation>
    <PMID>27306666</PMID>
  </reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 13, 2018</study_first_submitted>
  <study_first_submitted_qc>November 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 16, 2018</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Recurrent Glioblastoma</keyword>
  <keyword>Carboplatin</keyword>
  <keyword>Ultrasound</keyword>
  <keyword>Blood-brain barrier</keyword>
  <keyword>Glioblastoma</keyword>
  <keyword>SonoCloud</keyword>
  <keyword>Low Intensity Pulsed Ultrasound (LIPU)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

